UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

Breast cancer research and treatment, 2021-12, Vol.190 (3), p.415-424

2021

Volltextzugriff (PDF)

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer

European journal of cancer (1990), 2011-09, Vol.47 (14), p.2091-2098

2011

Volltextzugriff (PDF)

Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients

Future oncology (London, England), 2015-05, Vol.11 (10), p.1493-1500

2015

Volltextzugriff (PDF)

Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification

Breast (Edinburgh), 2013-12, Vol.22 (6), p.1101-1107

2013

Volltextzugriff (PDF)

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Breast cancer research and treatment, 2019-04, Vol.174 (2), p.433-442

2019

Volltextzugriff (PDF)

Abstract P1-03-08: New diagnostic tools for bone health assessment: Perspectives in medical oncology

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-03-08

2019

Volltextzugriff (PDF)

P327 - BESTEST®: a new diagnostic opportunity for bone structure evaluation in oncology

Breast (Edinburgh), 2019-03, Vol.44, p.S128-S129

2019

Volltextzugriff (PDF)

BESTEST®: a new diagnostic opportunity for bone structure evaluation in oncology

Breast (Edinburgh), 2019-03, Vol.44, p.S128-S129

2019

Volltextzugriff (PDF)

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study

British journal of cancer, 2005-08, Vol.93 (4), p.406-411

2005

Volltextzugriff (PDF)

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Breast (Edinburgh), 2019-12, Vol.48, p.7-16

2019

Volltextzugriff (PDF)

Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer

European journal of cancer (1990), 1997-02, Vol.33 (2), p.301-303

1997

Volltextzugriff (PDF)

Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Old drugs, new opportunities Preliminary results of the VICTOR-6 study

Annals of oncology, 2017-09, Vol.28, p.v100-v100

2017

Volltextzugriff (PDF)

P-176 Nabpaclitaxel plus gemcitabine as induction chemotherapy (CT) followed by chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)

Annals of oncology, 2015-06, Vol.26, p.iv51

2015

Volltextzugriff (PDF)

Clinical and pathological factors predicting long-term disease control with lapatinib and capecitabine for patients with HER2 positive metastastic breast cancer: results from a multicenter retrospective study

Annals of oncology, 2015-10, Vol.26, p.vi13

2015

Volltextzugriff (PDF)

Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer

Lung cancer, 2001-12, Vol.34, p.37-46

2001

Volltextzugriff (PDF)

Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes

Breast (Edinburgh), 1996-04, Vol.5 (2), p.82-88

1996

Volltextzugriff (PDF)

Tumor markers in breast cancer follow-up: A potentially useful parameter still awaiting definitive assessment

Annals of oncology, 1995, Vol.6 (suppl-2), p.S31-S35

1995

Volltextzugriff (PDF)

Abstract P1-11-20: Open-Label Phase II Study of Neoadjuvant Bevacizumab Combined with FEC→Paclitaxel in Patients with Inflammatory or Locally Advanced Breast Cancer

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P1-P1-11-20

2010

Volltextzugriff (PDF)

Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.3149

2009

Volltextzugriff (PDF)

Once-weekly epoetin beta treatment in anemic patients with breast cancer receiving chemotherapy: Interim analysis of a multicenter, single arm study

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.19605-19605

2007

Volltextzugriff (PDF)

Evaluation of Critical Differences of CEA and CA15.3 Levels in Serial Samples from Patients Operated for Breast Cancer

The International journal of biological markers, 1994-07, Vol.9 (3), p.135-139

1994

Volltextzugriff (PDF)

Lethal neurotoxicity associated to azidothymidine therapy

Journal of neurology, neurosurgery and psychiatry, 1989-04, Vol.52 (4), p.544-545

1989

Volltextzugriff (PDF)

Risk factors for human immunodeficiency virus (HIV) infection among homosexual and bisexual men in a region at low risk for AIDS: the northeastern part of Italy

Revue d'épidémiologie et de santé publique, 1989, Vol.37 (2), p.103-108

1989

Volltextzugriff (PDF)

Human immunodeficiency virus infection in transfused and untransfused cancer patients not belonging to known groups at increased risk for AIDS

Haematologica (Roma), 1988-03, Vol.73 (2), p.160

1988

Volltextzugriff (PDF)

Comparison of presenting clinical and laboratory findings of patients with persistent generalized lymphadenopathy (PGL) syndrome and malignant lymphoma (ML)

Haematologica (Roma), 1987-11, Vol.72 (6), p.563

1987

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77)
Mit Volltextzugriff
(69)

Publikationsform

Sprache

Englisch
(85)

Erscheinungsjahr

n.n

Thema

Science & Technology
(47)
Life Sciences & Biomedicine
(35)
Humans
(34)
Oncology
(25)
Female
(23)
Breast Cancer
(19)
Adult
(18)
Aged
(17)
Middle Aged
(17)
Breast Neoplasms - Drug Therapy
(16)
Breast Neoplasms - Pathology
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Technology
(10)
Tumors
(9)
Aged, 80 And Over
(8)
Aids/hiv
(8)
Chemotherapy
(8)
Computer Science
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer

Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients

Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Abstract P1-03-08: New diagnostic tools for bone health assessment: Perspectives in medical oncology

P327 - BESTEST®: a new diagnostic opportunity for bone structure evaluation in oncology

BESTEST®: a new diagnostic opportunity for bone structure evaluation in oncology

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer

Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Old drugs, new opportunities Preliminary results of the VICTOR-6 study

P-176 Nabpaclitaxel plus gemcitabine as induction chemotherapy (CT) followed by chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)

Clinical and pathological factors predicting long-term disease control with lapatinib and capecitabine for patients with HER2 positive metastastic breast cancer: results from a multicenter retrospective study

Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer

Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes

Tumor markers in breast cancer follow-up: A potentially useful parameter still awaiting definitive assessment

Abstract P1-11-20: Open-Label Phase II Study of Neoadjuvant Bevacizumab Combined with FEC→Paclitaxel in Patients with Inflammatory or Locally Advanced Breast Cancer

Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer

Once-weekly epoetin beta treatment in anemic patients with breast cancer receiving chemotherapy: Interim analysis of a multicenter, single arm study

Evaluation of Critical Differences of CEA and CA15.3 Levels in Serial Samples from Patients Operated for Breast Cancer

Lethal neurotoxicity associated to azidothymidine therapy

Risk factors for human immunodeficiency virus (HIV) infection among homosexual and bisexual men in a region at low risk for AIDS: the northeastern part of Italy

Human immunodeficiency virus infection in transfused and untransfused cancer patients not belonging to known groups at increased risk for AIDS

Comparison of presenting clinical and laboratory findings of patients with persistent generalized lymphadenopathy (PGL) syndrome and malignant lymphoma (ML)

Suchergebnisse filtern